Enhancing Predictive Accuracy in Immunotherapy Models Through Data Integration and Parameter Identifiability

Immune checkpoint inhibitors (ICIs), a class of immunotherapy, offer promising benefits but face challenges such as low response rates to be used as a broadly effective treatment for all patients. In this study, we use a set of ordinary different equation (ODE) models and bladder cancer in vivo data as a case study to outline a biologically informed, data-driven framework for formulating, calibrating and validating immunotherapy models, and thus ensuring their predictive reliability. We consider multiple treatment scenarios and distinct immune cell-mediated killing mechanisms for tumor cells of different antigenicity. By integrating sensitivity analysis and identifiability analysis with targeted experimental design, we demonstrate how mathematical models can move beyond qualitative insight to quantitative prediction. We generate virtual cohorts to show that insufficient data integration leads to systematically overestimated therapeutic benefits of ICIs. We also explore dosing schedules that enhance survival or reduce dosage without compromising survival. ### Competing Interest Statement The authors have declared no competing interest. NIH/NCI, U01CA243075, K08, CA234392